HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, X. Articles by Wu, J. Search for Related Content PubMed PubMed Citation Articles by Wang, X. Articles by Wu, J.

Role of Proteasomes in T Cell Activation and Proliferation¹

Xin Wang^*, Hongyu Luo^*, Huifang Chen^*, William Duguid and Jiangping Wu^2,*,,§

^* Laboratory of Transplantation Immunology, Louis-Charles Simard Research Center, and Nephrology Service, Notre-Dame Hospital, University of Montreal; and Montreal General Hospital and ^§ Department of Surgery, McGill University, Montreal, Canada

The role of proteasomes in T cell activation, proliferation, and apoptosis was investigated using a proteasome-specific inhibitor lactacystin (LAC). Inhibition of the proteasome activity by LAC repressed the mitogen-induced T cell proliferation. The proteasome activity was definitively required for the T cells to progress from the G₀ to S phase. It was necessary to optimize the progress from the G₁/S boundary to the G₂/M phase, but not for the progress from the G₂/M phase to the next G₁ phase. Probably as a result of a blockage of cell cycle progress, the cycling, but not the resting, T cells underwent apoptosis when treated with LAC. Mechanistically, we have found that cyclin-dependent kinase-2 (CDK2) and the cyclin E-associated kinase (largely CDK2), but not CDK4, in the G₁ phase were strongly inhibited by LAC. This could be an important mechanism for the proteasome to regulate the cell cycle. The degradation of cyclin E in the late G₁ and early S phases was dependent on the proteasome, although it was unlikely that this accounted for the observed inhibition of T cell proliferation. There was a reduced decay of p27^Kip1 in the late G₁ phase when the proteasome activity was suppressed, and this might be a contributing mechanism for the observed inhibition of CDK2 activity. Interestingly, p21^Cip1 was up-regulated during the G₁ phase, and the up-regulation was inhibited by LAC. Our study shows that the proteasome plays pivotal roles in regulating T cell activation and proliferation, and its effect is probably exerted through multiple mechanisms.

This article has been cited by other articles:

				C. M. Caudill, K. Jayarapu, L. Elenich, J. J. Monaco, R. A. Colbert, and T. A. Griffin T Cells Lacking Immunoproteasome Subunits MECL-1 and LMP7 Hyperproliferate in Response to Polyclonal Mitogens J. Immunol., April 1, 2006; 176(7): 4075 - 4082. [Abstract] [Full Text] [PDF]

				O. Aktas, T. Prozorovski, A. Smorodchenko, N. E. Savaskan, R. Lauster, P.-M. Kloetzel, C. Infante-Duarte, S. Brocke, and F. Zipp Green Tea Epigallocatechin-3-Gallate Mediates T Cellular NF-{kappa}B Inhibition and Exerts Neuroprotection in Autoimmune Encephalomyelitis J. Immunol., November 1, 2004; 173(9): 5794 - 5800. [Abstract] [Full Text] [PDF]

				K. Sun, L. A. Welniak, A. Panoskaltsis-Mortari, M. J. O'Shaughnessy, H. Liu, I. Barao, W. Riordan, R. Sitcheran, C. Wysocki, J. S. Serody, et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib PNAS, May 25, 2004; 101(21): 8120 - 8125. [Abstract] [Full Text] [PDF]

				V. Marshansky, X. Wang, R. Bertrand, H. Luo, W. Duguid, G. Chinnadurai, N. Kanaan, M. D. Vu, and J. Wu Proteasomes Modulate Balance Among Proapoptotic and Antiapoptotic Bcl-2 Family Members and Compromise Functioning of the Electron Transport Chain in Leukemic Cells J. Immunol., March 1, 2001; 166(5): 3130 - 3142. [Abstract] [Full Text] [PDF]

				J. K. Moore, R. I. Scheinman, and D. Bellgrau The Identification of a Novel T Cell Activation State Controlled by a Diabetogenic Gene J. Immunol., January 1, 2001; 166(1): 241 - 248. [Abstract] [Full Text] [PDF]

				A. Frankel, S. Man, P. Elliott, J. Adams, and R. S. Kerbel Lack of Multicellular Drug Resistance Observed in Human Ovarian and Prostate Carcinoma Treated with the Proteasome Inhibitor PS-341 Clin. Cancer Res., September 1, 2000; 6(9): 3719 - 3728. [Abstract] [Full Text]

				M. Chiravuri, T. Schmitz, K. Yardley, R. Underwood, Y. Dayal, and B. T. Huber A Novel Apoptotic Pathway in Quiescent Lymphocytes Identified by Inhibition of a Post-Proline Cleaving Aminodipeptidase: A Candidate Target Protease, Quiescent Cell Proline Dipeptidase J. Immunol., September 15, 1999; 163(6): 3092 - 3099. [Abstract] [Full Text] [PDF]

				J. Adams, V. J. Palombella, E. A. Sausville, J. Johnson, A. Destree, D. D. Lazarus, J. Maas, C. S. Pien, S. Prakash, and P. J. Elliott Proteasome Inhibitors: A Novel Class of Potent and Effective Antitumor Agents Cancer Res., June 1, 1999; 59(11): 2615 - 2622. [Abstract] [Full Text] [PDF]

				E. Geier, G. Pfeifer, M. Wilm, M. Lucchiari-Hartz, W. Baumeister, K. Eichmann, and G. Niedermann A Giant Protease with Potential to Substitute for Some Functions of the Proteasome Science, February 12, 1999; 283(5404): 978 - 981. [Abstract] [Full Text]